Tao Qm
Zhejiang University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tao Qm.
Cardiovascular Drugs and Therapy | 2005
Yuangang Qiu; Jianhua Zhu; Tao Qm; Ping Zheng; Chen J; Shen-Jiang Hu; Zhang Fr; Liangrong Zheng; Lili Zhao; Xue-Yan Yao
The aim of our study was to evaluate whether captopril administered at night, can shift the circadian blood pressure (BP) from a nondipper to a dipper pattern in adequately controlled hypertensive patients, who continued their antihypertensive therapy. In a prospective, randomized, double blind, placebo-controlled designed study, we enrolled 121 treated, adequately controlled nondipping hypertensive patients. All patients were randomly assigned to 12.5 mg captopril or placebo treatment administered at night. In case of nondippers, the dosage of captopril or placebo was doubled after two weeks of treatment, while for dippers antihypertensive regimens were not changed. After another two weeks, all patients underwent ambulatory BP monitoring. Our results show that at the end of the active treatment period, the prevalence of a dipping diurnal BP pattern in the captopril group (70%) was significantly higher than that in the placebo group (9.8%, P < 0.001). Nighttime BP, night/day BP ratio, nighttime BP load and 24-h systolic BP were significantly lower after 4 weeks nighttime captopril treatment compared to baseline. In conclusion, the present study demonstrates for the first time that captopril administered at night can restore the diurnal BP rhythm and decrease the elevated night/day BP ratio in appropriately controlled, nondipper hypertensive patients. These results were mainly due to the decrease of nighttime BP.
The Journal of Thoracic and Cardiovascular Surgery | 2009
Qiqi Wang; Yuangang Qiu; Yujuan Zhu; Jianhua Zhu; Li-hong Wang; Xiao-sheng Hu; Shen-Jiang Hu; Liangrong Zheng; Tao Qm; Zhang Fr; Yun Zhang
OBJECTIVE Cyclophosphamide has a role of decreasing high-sensitivity C-reactive protein in the treatment of autoimmune disorders. The effect of cyclophosphasmide on high-sensitivity C-reactive protein was investigated in myocardial ischemia/reperfusion rat. METHODS Open-chest rats were submitted to 30 minutes of ischemia and followed for 3, 12, or 24 hours of reperfusion. All 72 rats survived and were divided into sham, ischemia/reperfusion (I/R) and cyclophosphamide groups, and each group included 3 time-point subgroups (3, 12, and 24 hours; n = 8 for each subgroup). Cyclophosphamide (0.75 g/m(2)) or saline was intraperitoneally administrated in the cyclophosphamide or I/R group. A polyethylene tube was inserted into the left ventricular cavity to detect left ventricular systolic pressure, left ventricular end-diastolic pressure, and maximum rate of rise or fall of left ventricular pressure. In the end, blood was collected for detection of high-sensitivity C-reactive protein, and hearts were harvested for histopathologic assessment and infarct size determination. RESULTS Compared with the I/R group, rats treated with cyclophosphamide showed a significant recovery in myocardial function with improved left ventricular systolic pressure (88.27 +/- 3.78 vs 68.62 +/- 3.78 mm Hg at 3 hours, 92.04 +/- 3.77 vs 63.74 +/- 4.87 mm Hg at 12 hours, and 90.41 +/- 3.98 vs 64.21 +/- 4.88 mm Hg at 24 hours; P < .05, respectively). Left ventricular end-diastolic pressure and maximum rate of rise or fall of left ventricular pressure also had similar trends. Infarct size was reduced (26.1% +/- 0.4% vs 40.4% +/- 0.4% at 3 hours, 21.6% +/- 0.4% vs 49.9% +/- 0.4% at 12 hours, and 21.6% +/- 0.4% vs 40.0% +/- 0.4% at 24 hours; P < .01, respectively). Histopathologic damage score was attenuated (1.83 +/- 0.14 vs 2.17 +/- 0.14 at 3 hours, 2.33 +/- 0.14 vs 3.17 +/- 0.14 at 12 hours, and 2.83 +/- 0.14 vs 3.83 +/- 0.14 at 24 hours; P < .01, respectively). Plasma high-sensitivity C-reactive protein concentration was significantly reduced (29.28 +/- 0.51 vs 32.26 +/- 0.51 ng/mL at 3 hours, 29.06 +/- 0.50 vs 31.8 +/- 0.51 ng/mL at 12 hours, and 28.61 +/- 0.51 vs 31.86 +/- 0.51 ng/mL at 24 h; P < .01, respectively). CONCLUSION Cyclophosphamide protects myocardial ischemia/reperfusion injury in the rat with a decrease in plasma concentration of high-sensitivity C-reactive protein.
Journal of the American College of Cardiology | 2007
Xing-Xiang Wang; Zhang Fr; Yunpeng Shang; Zhu Jh; Xudong Xie; Tao Qm; Jianhua Zhu; Chen J
Chinese journal of epidemiology | 2003
Yuangang Qiu; Liangrong Zheng; Chen Jz; Jun Zhu; Zhang Fr; Xu Y; Zhao Ll; Tao Qm
Chinese journal of epidemiology | 2004
Yuangang Qiu; Xue-Yan Yao; Tao Qm; Ping Zheng; Chen Jz; Jun Zhu; Zhang Fr; Liangrong Zheng; Zhao Ll
Chinese journal of cardiovascular diseases | 2007
Zhu Yj; Liu Zy; Ying-Xuan Chen; Ping Zheng; Jun Zhu; Tao Qm; Liangrong Zheng; Wang Qq; Shi Mj; Yuangang Qiu
Archive | 2010
Tao Qm; Jianhua Zhu; Chen J; Xing-Xiang Wang; Zhang Fr; Yunpeng Shang; Zhu Jh; Xudong Xie
Chinese journal of cardiovascular diseases | 2006
Yu Chen; Yuangang Qiu; Jun Zhu; Ping Zheng; Chen Jz; Zhang Fr; Zhao Ll; Tao Qm; Liangrong Zheng
Chinese journal of cardiovascular diseases | 2005
Jun Zhu; Yuangang Qiu; Chen Jz; Zhang Fr; Fu Gs; Shen Fr; Huang Wj; Wang J; Zhao Ll; Tao Qm; Liangrong Zheng
Chinese journal of epidemiology | 2003
Yuangang Qiu; Zhang Fr; Chen Jz; Jun Zhu; Tao Qm; Liangrong Zheng; Xu Y; Zhao Ll